pubmed.ncbi.nlm.nih.gov

Assessment of genetically modified Maize MON 87429 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2019-161) - PubMed

  • ️Sat Jan 01 2022

. 2022 Nov 18;20(11):e07589.

doi: 10.2903/j.efsa.2022.7589. eCollection 2022 Nov.

Assessment of genetically modified Maize MON 87429 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA-GMO-NL-2019-161)

EFSA Panel on Genetically Modified Organisms (GMO) et al. EFSA J. 2022.

Abstract

Maize MON 87429 was developed to confer tolerance to dicamba, glufosinate, quizalofop and 2,4-D herbicides. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize MON 87429 and its conventional counterpart needs further assessment, except for the levels of phytic acid in grains, which do not raise nutritional and safety concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the DMO, PAT, FT_T and CP4 EPSPS proteins as expressed in maize MON 87429. The GMO Panel finds no evidence that the genetic modification impacts the overall safety of maize MON 87429. In the context of this application, the consumption of food and feed from maize MON 87429 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that maize MON 87429 is as safe as the conventional counterpart and non-GM maize reference varieties tested, and no post-market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize MON 87429 grains into the environment, this would not raise environmental safety concerns. The post-market environmental monitoring plan and reporting intervals are in line with the intended uses of maize MON 87429. The GMO Panel concludes that maize MON 87429, as described in this application, is as safe as its conventional counterpart and the tested non-GM maize reference varieties with respect to potential effects on human and animal health and the environment.

Keywords: CP4 EPSPS; DMO; FT_T; GM; MON 87429; PAT; genetic engineering; maize (Zea mays).

© 2022 Wiley‐VCH Verlag GmbH & Co. KgaA on behalf of the European Food Safety Authority.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Berg G, Roskot N and Smalla K, 1999. Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia . Journal of Clinical Microbiology, 37, 3594–3600. - PMC - PubMed
    1. Breiteneder H and Mills EN, 2005. Molecular properties of food allergens. Journal of Allergy and Clinical Immunology, 115, 14–23. - PubMed
    1. Calza L, Manfredi R and Chiodo F, 2003. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10‐year surveillance study. Infection, 31, 155–161. - PubMed
    1. Chekan JR, Ongpipattanakul C, Wright TR, Zhang B, Bollinger JM, Rajakovich LJ, Krebs C, Cicchillo RM and Nair SK, 2019. Molecular basis for enantioselective herbicide degradation imparted by aryloxyalkanoate dioxygenases in transgenic plants. Proceedings of the National Academy of Sciences of the United States of America, 116, 13299–13304. - PMC - PubMed
    1. Codex Alimentarius , 2009. Foods derived from modern biotechnology. Codex Alimentarius Commission, Joint FAO/WHO Food Standards Programme, Rome. Available online: http://www.fao.org/docrep/011/a1554e/a1554e00.htm